Neuropsychiatric Disease and Treatment · 2006 · 41 citations · 41 references
MedicinePharmacologyPharmacotherapyNeuropharmacologyPharmacodynamicsPsychopharmacologyAttention-deficit/hyperactivity DisorderChild PsychopharmacologyPediatric PharmacokineticsPediatric PharmacologyPsychopharmacology In ChildrenStimulant TherapyAdhd PharmacotherapyAdhd TreatmentAdult AdhdChildhood AdhdNorepinephrine Reuptake InhibitionNorepinephrine Transporter InhibitionPediatric Stimulant MedicationsSerotonin-norepinephrine Reuptake Inhibitor Treatment
Attention deficit hyperactivity disorder (ADHD) is a common chronic condition with childhood onset that can continue into adulthood. Medication is a fundamental element in the management of this disorder. Atomoxetine is the newest nonstimulant medication approved by the United States Food and Drug Administration (FDA) for the treatment of ADHD. It is the only nonstimulant medication approved by the FDA for treatment of adult ADHD. Atomoxetine is a norepinephrine reuptake inhibitor that selectively inhibits the presynaptic norepinephrine transporter. A growing body of literature supports the use of atomoxetine both in children and adults with ADHD. This paper summarizes information from the literature about atomoxetine, including pharmacokinetics, pharmacodynamics, clinical trials, dosing, and side-effects.
41
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
David Michelson, Lenard A. Adler, Thomas Spencer et al. · Biological Psychiatry · 2003 · 789 citations
Douglas K. Kelsey, Calvin R. Sumner, Charles D. Casat et al. · PEDIATRICS · 2004 · 467 citations